Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Net Cash Flow (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Net Cash Flow data on record, last reported at $1.5 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 65.66% year-over-year to $1.5 million; the TTM value through Sep 2025 reached -$2.2 million, up 96.76%, while the annual FY2024 figure was $5.8 million, 138.79% up from the prior year.
  • Net Cash Flow reached $1.5 million in Q3 2025 per ZNTL's latest filing, up from -$4.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $230.3 million in Q2 2023 and bottomed at -$155.8 million in Q3 2023.
  • Average Net Cash Flow over 4 years is -$1.4 million, with a median of -$640000.0 recorded in 2024.
  • The widest YoY moves for Net Cash Flow: up 846.56% in 2023, down 16057.34% in 2023.
  • A 4-year view of Net Cash Flow shows it stood at $518000.0 in 2022, then tumbled by 16057.34% to -$82.7 million in 2023, then skyrocketed by 91.02% to -$7.4 million in 2024, then skyrocketed by 119.85% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $1.5 million in Q3 2025, -$4.3 million in Q2 2025, and $8.0 million in Q1 2025.